Methods of administering solriamfetol to lactating women
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
1. A method of treating excessive daytime sleepiness, attention deficit hyperactivity disorder, binge eating disorder, depression, or cognitive impairment in a lactating human mother feeding an infant with her breast milk, comprising:
orally administering solriamfetol to the mother at a once-daily dose of about 150 mg; and
feeding the infant the breast milk obtained from the mother at least about 5 hours after administration of the solriamfetol to the mother;
wherein the daily infant dose of solriamfetol is reduced to about 0.3 mg or lower; and
wherein the potential for adverse events in the infant due to the solriamfetol is decreased.
2. The method of claim 1 , wherein the adverse event is agitation, insomnia, anorexia, or reduced weight gain.
3. The method of claim 1 , wherein the infant does not experience agitation, insomnia, anorexia, or reduced weight gain due to solriamfetol from the breast milk.
4. The method of claim 1 , where the excessive daytime sleepiness is due to narcolepsy, obstructive sleep apnea, shift work disorder, major depression, or Parkinson's disease.
5. The method of claim 1 , wherein the lactating mother is from 1 day to 24 months postpartum.
6. The method of claim 1 , wherein the lactating mother is from 10 days to 12 months postpartum.
7. The method of claim 1 , wherein the lactating mother is between the ages of 18 and 45 years.
8. A method of treating excessive daytime sleepiness, attention deficit hyperactivity disorder, binge eating disorder, depression, or cognitive impairment in a lactating human mother feeding an infant with her breast milk, comprising:
orally administering solriamfetol to the mother at a once-daily dose of about 75 mg; and
feeding the infant the breast milk obtained from the mother at least about 5 hours after administration of the solriamfetol to the mother;
wherein the daily infant dose of solriamfetol is reduced to about 0.15 mg or lower; and
wherein the potential for adverse events in the infant due to the solriamfetol is decreased.
9. The method of claim 8 , wherein the adverse event is agitation, insomnia, anorexia, or reduced weight gain.
10. The method of claim 8 , wherein the infant does not experience agitation, insomnia, anorexia, or reduced weight gain due to solriamfetol from the breast milk.
11. The method of claim 8 , where the excessive daytime sleepiness is due to narcolepsy, obstructive sleep apnea, shift work disorder, major depression, or Parkinson's disease.
12. The method of claim 8 , wherein the lactating mother is from 1 day to 24 months postpartum.
13. The method of claim 8 , wherein the lactating mother is from 10 days to 12 months postpartum.
14. The method of claim 8 , wherein the lactating mother is between the ages of 18 and 45 years.
15. A method of treating excessive daytime sleepiness, attention deficit hyperactivity disorder, binge eating disorder, depression, or cognitive impairment in a lactating human mother feeding an infant with her breast milk, comprising:
orally administering solriamfetol to the mother at a once-daily dose of about 150 mg; and
feeding the infant the breast milk obtained from the mother at least about 5 hours after administration of the solriamfetol to the mother;
wherein the daily infant dose of solriamfetol is reduced to about 0.3 mg or lower; and
wherein the exposure of the infant to the solriamfetol from the breast milk is decreased.
16. The method of claim 15 , wherein the infant does not experience agitation, insomnia, anorexia, or reduced weight gain due to solriamfetol from the breast milk.
17. The method of claim 15 , where the excessive daytime sleepiness is due to narcolepsy, obstructive sleep apnea, shift work disorder, major depression, or Parkinson's disease.
18. The method of claim 15 , wherein the lactating mother is from 1 day to 24 months postpartum.
19. The method of claim 15 , wherein the lactating mother is from 10 days to 12 months postpartum.
20. The method of claim 15 , wherein the lactating mother is between the ages of 18 and 45 years.
21. A method of treating excessive daytime sleepiness, attention deficit hyperactivity disorder, binge eating disorder, depression, or cognitive impairment in a lactating human mother feeding an infant with her breast milk, comprising:
orally administering solriamfetol to the mother at a once-daily dose of about 75 mg; and
feeding the infant the breast milk obtained from the mother at least about 5 hours after administration of the solriamfetol to the mother;
wherein the daily infant dose of solriamfetol is reduced to about 0.15 mg or lower; and
wherein the exposure of the infant to the solriamfetol from the breast milk is decreased.
22. The method of claim 21 , wherein the infant does not experience agitation, insomnia, anorexia, or reduced weight gain due to solriamfetol from the breast milk.
23. The method of claim 21 , where the excessive daytime sleepiness is due to narcolepsy, obstructive sleep apnea, shift work disorder, major depression, or Parkinson's disease.
24. The method of claim 21 , wherein the lactating mother is from 1 day to 24 months postpartum.
25. The method of claim 21 , wherein the lactating mother is from 10 days to 12 months postpartum.
26. The method of claim 21 , wherein the lactating mother is between the ages of 18 and 45 years.